ERBB2 and breast carcinoma: A novel aspect of our study is that we focused on the feasibility of HER2 testing in CTCs from a heavily pretreated metastatic breast cancer patient population and comparison tested the two leading CTC platforms, CellSearch® and CTC-Chip.